Genexine Announces Merger with EPD Biotherapeutics (EPD Bio)

mdxhealth to Acquire Bio-Techne’s Exosome Diagnostics Business (ExoDx Prostate)

August 5, 2025

Healthcare Services

Bio-Techne Corporation has reached an agreement for mdxhealth SA to acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test and CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to proprietary exosome-based technology for ongoing kit development, and expects the transaction to be completed in the first quarter of fiscal 2026.

Harmony Biosciences Acquires Epygenix Therapeutics

April 30, 2024

Biotechnology

Harmony Biosciences has acquired Epygenix Therapeutics, adding a late-stage rare epilepsy franchise (including EPX-100 and EPX-200) to its CNS pipeline. Harmony paid $35 million in cash with up to $130 million in development/regulatory milestones and up to $515 million in potential sales milestones to complete the transaction.

Leinco Technologies Acquires QED Biosciences from Genovis

September 3, 2024

Biotechnology

Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

STEMCELL Technologies Acquires Propagenix Inc.

January 19, 2024

Biotechnology

STEMCELL Technologies, Canada’s largest biotechnology company, acquired Propagenix Inc., a Gaithersburg, Maryland biotechnology firm focused on epithelial cell biology and its patented EpiX technology. The acquisition includes Propagenix’s assets, IP (including its Conditional Reprogramming license with Georgetown University) and existing business arrangements, enabling STEMCELL to develop EpiX-based products for clinical applications and expand its regenerative-medicine capabilities.